🌙 Link Found Between Melatonin Use and Heart Failure Risk

 New Research Raises Important Questions

Melatonin is widely known as the “sleep hormone”, often used as a supplement to improve sleep quality, reduce jet lag, or manage insomnia. It is generally considered safe — unlike many sleep medications.

However, a new large-scale study has uncovered a concerning association:
➡ Regular melatonin supplement intake may be linked to increased heart failure risk in certain individuals.

Researchers emphasize that melatonin is not harmful for everyone, but it may interact with cardiovascular mechanisms more deeply than previously understood.


🔬 What Did the Study Find?

Scientists discovered:

✅ Higher melatonin levels were found in a subset of heart failure patients
✅ Chronic use of melatonin supplements may alter heart function over time
✅ Potential risk is higher for those with existing cardiovascular disease

Why is this unexpected?

Melatonin actually has antioxidant and anti-inflammatory properties, leading many to believe it would protect the heart.

But the new data suggests long-term supplementation may disrupt:
✅ Blood pressure regulation
✅ Heart rhythm mechanisms
✅ Autonomic nervous system balance

🫀 How Melatonin Might Influence Heart Failure

➡ This does not mean melatonin causes heart failure — but it could worsen vulnerability in at-risk people.

👥 Who Should Be More Cautious?

Doctors advise careful use if you have:

  • Heart failure (HFpEF or HFrEF)

  • Uncontrolled hypertension

  • Sleep apnea

  • Atrial fibrillation or arrhythmias

  • Diabetes with cardiac complications

People with no heart disease risk appear less affected.

💊 Supplements Are Not One-Size-Fits-All

Many assume over-the-counter melatonin is harmless, but:

  • Supplements are often 3–10x more potent than natural melatonin levels

  • Quality varies — some contain inconsistently high doses

  • Self-prescription avoids necessary medical evaluation

😴 Why People Prefer Melatonin


🩺 Should You Stop Taking Melatonin?

Experts recommend:

✅ If you have heart failure → Talk to your cardiologist before using it
✅ If you rely on melatonin long-term → Review your dosage and need
✅ Consider natural sleep strategies first:

  • Maintain consistent sleep schedule

  • Limit screen exposure before bed

  • Reduce caffeine late in the day

  • Manage stress and exercise regularly

🔍 What’s Next in Research?

Scientists plan to determine:

  • Exact dosage that increases risk

  • Which cardiac patients are most vulnerable

  • Whether timing of supplementation affects outcomes

  • Long-term effects beyond sleep benefits

This knowledge may help design personalized sleep therapies for cardiac patients.

✅ Conclusion

Melatonin remains a useful supplement — but not completely risk-free.
This newly identified link urges:

⚠ More caution
⚠ Medical guidance
⚠ Ongoing research

Understanding the heart–sleep connection could dramatically improve prevention of heart failure, one of the world’s deadliest conditions.

To know more visit: https://www.cardiology.scientexconference.com/sessions/Advancements-and-Current-Research-in-Cardiology

Comments

Post a Comment

Popular posts from this blog

Image
  Ventricular Assist Device – Miniature The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation , has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty , huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size , battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms. Cardiac Decellularization and Engineered Heart Tissue Promising new direction...
Read more
Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more